RecruitingNot ApplicableNCT07366099

Al18F-NOTA-LM3 PET/CT in Patients With TIO

Application of Al18F-NOTA-LM3 PET/CT in the Diagnosis and Evaluation of Tumor-Induced Osteomalacia

Sponsor

Peking Union Medical College Hospital

Enrollment

40 participants

Start Date

Mar 30, 2023

Study Type

INTERVENTIONAL

Conditions

Tumor-Induced Osteomalacia

Summary

This is a pilot study to assess the value of whole-body Al18F-NOTA-LM3 PET/CT in patients with tumor-induced osteomalacia.

Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Diagnostic Test: 68Ga-DOTATATE and a drug called Diagnostic Test: Al18F-NOTA-LM3 for people with tumor-induced osteomalacia. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 80 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGDiagnostic Test: Al18F-NOTA-LM3

Al18F-NOTA-LM3 will be injected into the patients. Patients will undergo a whole-body PET/CT scan 60-120 minutes after injection.

DRUGDiagnostic Test: 68Ga-DOTATATE

68Ga-DOTATATE will be injected into the patients. Patients will undergo a whole-body PET/CT scan 40-60 minutes after injection.

Locations(1)

Peking Union Medical College Hospital

Beijing, Beijing Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07366099